The Technical Analyst
Compugen Ltd [CGEN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Compugen Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.05% $1.880
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 168.32 mill |
| EPS: | -0.210 |
| P/E: | -8.95 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 89.53 mill |
| Avg Daily Volume: | 0.607 mill |
| RATING 2024-04-18 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -8.95 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.52x |
| Company: PE -8.95 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.706 - 2.05 ( +/- 9.26%) |
| ATR Model: 14 days |
Forecast:
16:00 - $1.880
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.880
Forecast 2: 16:00 - $1.880
Forecast 3: 16:00 - $1.880
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.880 (-1.05% ) |
| Volume | 0.309 mill |
| Avg. Vol. | 0.607 mill |
| % of Avg. Vol | 50.91 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CGEN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $2.15 | N/A | Active |
|---|
CGEN
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Last 10 Buy Signals
Latest Press Releases
2024-04-10 07:00:00 - Press Release
Compugen Publishes Paper In Cancer Immunology Research Demonstrating Therapeutic Potential Of Com503
Holon, israel , april 10, 2024 /prnewswire/ -- compugen ltd. (nasdaq: cgen) (tase: cgen) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the simultaneous online publication of a peer reviewed paper titled 'unleashing natural il-18 activity using an anti-il-18bp blocker antibody induces potent immune stimulation and anti-tumor effects' link, in cancer immunology research, a journal of the american association for cancer research with a presentation at the american association for cancer research (aacr) annual meeting on april 5-11, 2024, in san diego, california.
2024-04-03 07:00:00 - Press Release
Compugen To Participate In Two Upcoming Investor Conferences
Holon, israel , april 3, 2024 /prnewswire/ -- compugen ltd. (nasdaq: cgen) (tase: cgen) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming investor conferences in april: 23rd annual needham virtual healthcare conference date: wednesday, april 10, 2024, at 8:00 am et location: virtual format: presentation canaccord genuity horizons in oncology virtual conference date: monday, april 15, 2024, at 9:00 am et location: virtual format: panel: novel immune checkpoints - there's more than one way to stimulate a t-cell live webcast of the presentation and a replay will be available on the investor relations section of compugen's website at www...
2024-03-11 07:00:00 - Press Release
Compugen Selected For Two Oral Presentations At The Keystone Symposium On Cancer Immunotherapy
Holon, israel , march 11, 2024 /prnewswire/ -- compugen ltd. (nasdaq: cgen) (tase: cgen) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it has been selected to give two oral presentations at the keystone symposium on cancer immunotherapy: beyond immune checkpoint blockade and overcoming resistance, taking place march 17-21, 2024, in whistler, canada.
2024-03-06 07:00:00 - Press Release
Compugen To Present Data Reflecting Its Diversified Immuno-oncology Pipeline At Aacr 2024
Holon, israel , march 6, 2024 /prnewswire/ -- compugen ltd. (nasdaq: cgen) (tase: cgen), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present data from its differentiated immuno-oncology preclinical and clinical pipeline, in two poster presentations at the american association for cancer research (aacr) annual meeting on april 5-11, 2024, in san diego, california.
2024-03-05 07:00:00 - Press Release
Compugen Reports Fourth Quarter And Full Year 2023 Results
Partnership with gilead on preclinical immuno-oncology program further validates compugen's computational discovery, research, and development capabilities catalyst rich 2024 expected with multiple data readouts and updates planned from compugen's diversified portfolio solid balance sheet with extended cash runway expected to fund operations into 2027 holon, israel , march 5, 2024 /prnewswire/ -- compugen ltd. (nasdaq: cgen) (tase: cgen) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today reported financial results for the fourth quarter and full year 2023 and provided a corporate update.
Latest News
2024-03-12 13:01:23 - Zacks Investment Research
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice
Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
2024-03-05 14:41:06 - Seeking Alpha
Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN ) Q4 2023 Earnings Conference Call March 5, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Sessa - Chief Financial Officer Eran Ophir - Chief Scientific Officer Michelle Mahler - Chief Medical Officer Conference Call Participants Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Partners Stephen Willey - Stifel Operator Ladies and gentlemen, thank you for joining us today.
2024-02-29 10:01:20 - Zacks Investment Research
Is a Surprise Coming for Compugen (CGEN) This Earnings Season?
Compugen (CGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2024-02-21 13:01:20 - Zacks Investment Research
Compugen (CGEN) is a Great Momentum Stock: Should You Buy?
Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
2024-01-22 22:14:30 - InvestorPlace
7 Speculative Stocks to Double Your Money THIS Year
While investors should probably direct the majority of their market-earmarked funds toward slow-and-steady ideas – à la Warren Buffett – sometimes, we end up with gambling money. And in that case, speculative stocks to double your money might make sense.
2024-01-10 08:01:12 - Seeking Alpha
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
2023-12-20 11:31:14 - Proactive Investors
Gilead Sciences and Compugen strike commercialization deal for immunotherapy program
Gilead Sciences, Inc. (NASDAQ:GILD) announced that it has entered into an agreement with Compugen Ltd (NASDAQ:CGEN) to exclusively license Compugen's pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate, which is targeting cancer. Per the agreement, Compugen will be responsible for the ongoing pre-clinical development and future Phase 1 study of COM503 after which Gilead will have the sole right to develop and commercialize the drug.
2023-12-19 10:23:56 - InvestorPlace
Why Are Stocks Up Today?
Stocks are up today and investors wondering why will want to keep reading as we have a breakdown of the market's rally on Tuesday! The big catalyst keeping stocks up today comes from high investor hopes for interest rate cuts in 2024.
2023-12-19 10:11:33 - InvestorPlace
Why Is Compugen (CGEN) Stock Up 189% Today?
Compugen (NASDAQ: CGEN ) stock is rocketing higher on Tuesday after announcing an exclusive licensing agreement with Gilead Sciences (NASDAQ: GILD ). According to a press release from Compugen, this agreement covers its anti-IL-18 binding protein program.
2023-12-19 07:13:00 - Market Watch
Compugen stock rockets on anti-tumor drug deal with Gilead
Compugen Ltd.'s stock CGEN, -3.36% was up by 113% in premarket trading on Tuesday after the company said it agreed to sell exclusive rights to Gilead Sciences Inc. GILD, -1.03% for later stage development and commercialization of Anti-IL 18 binding protein antibodies with potential to treat various types of tumors.